Annual Cash & Cash Equivalents
$102.69 M
-$8.21 M-7.40%
30 September 2024
Summary:
Arrowhead Pharmaceuticals annual cash & cash equivalents is currently $102.69 million, with the most recent change of -$8.21 million (-7.40%) on 30 September 2024. During the last 3 years, it has fallen by -$81.75 million (-44.32%). ARWR annual cash & cash equivalents is now -53.70% below its all-time high of $221.80 million, reached on 30 September 2019.ARWR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$102.69 M
+$35.49 M+52.81%
30 September 2024
Summary:
Arrowhead Pharmaceuticals quarterly cash and cash equivalents is currently $102.69 million, with the most recent change of +$35.49 million (+52.81%) on 30 September 2024. Over the past year, it has increased by +$44.47 million (+76.39%). ARWR quarterly cash and cash equivalents is now -77.73% below its all-time high of $461.03 million, reached on 31 December 2019.ARWR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.4% | +76.4% |
| 3 y3 years | -44.3% | +12.1% |
| 5 y5 years | -53.7% | -77.7% |
ARWR Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -44.3% | at low | -47.3% | +76.4% |
| 5 y | 5 years | -53.7% | at low | -77.7% | +76.4% |
| alltime | all time | -53.7% | >+9999.0% | -77.7% | >+9999.0% |
Arrowhead Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | $102.69 M(-7.4%) | $102.69 M(+52.8%) |
| June 2024 | - | $67.20 M(-47.4%) |
| Mar 2024 | - | $127.70 M(+119.4%) |
| Dec 2023 | - | $58.22 M(-47.5%) |
| Sept 2023 | $110.89 M(+2.7%) | $110.89 M(+5.3%) |
| June 2023 | - | $105.33 M(-22.0%) |
| Mar 2023 | - | $134.96 M(-30.8%) |
| Dec 2022 | - | $194.95 M(+80.5%) |
| Sept 2022 | $108.00 M(-41.4%) | $108.00 M(-22.5%) |
| June 2022 | - | $139.44 M(+61.4%) |
| Mar 2022 | - | $86.41 M(-5.7%) |
| Dec 2021 | - | $91.59 M(-50.3%) |
| Sept 2021 | $184.43 M(+28.5%) | $184.43 M(-43.4%) |
| June 2021 | - | $325.98 M(-12.5%) |
| Mar 2021 | - | $372.38 M(+166.1%) |
| Dec 2020 | - | $139.92 M(-2.6%) |
| Sept 2020 | $143.58 M(-35.3%) | $143.58 M(-34.5%) |
| June 2020 | - | $219.32 M(-14.5%) |
| Mar 2020 | - | $256.65 M(-44.3%) |
| Dec 2019 | - | $461.03 M(+107.9%) |
| Sept 2019 | $221.80 M(+636.1%) | $221.80 M(+17.8%) |
| June 2019 | - | $188.33 M(+16.5%) |
| Mar 2019 | - | $161.64 M(-14.8%) |
| Dec 2018 | - | $189.77 M(+529.8%) |
| Sept 2018 | $30.13 M(+21.3%) | $30.13 M(+7.6%) |
| June 2018 | - | $28.00 M(-59.9%) |
| Mar 2018 | - | $69.81 M(+505.4%) |
| Dec 2017 | - | $11.53 M(-53.6%) |
| Sept 2017 | $24.84 M(-70.9%) | $24.84 M(-35.3%) |
| June 2017 | - | $38.38 M(-37.8%) |
| Mar 2017 | - | $61.72 M(-39.6%) |
| Dec 2016 | - | $102.11 M(+19.6%) |
| Sept 2016 | $85.37 M(+5.1%) | $85.37 M(+95.7%) |
| June 2016 | - | $43.62 M(-13.3%) |
| Mar 2016 | - | $50.30 M(-19.1%) |
| Dec 2015 | - | $62.17 M(-23.5%) |
| Sept 2015 | $81.21 M(-38.7%) | $81.21 M(-6.9%) |
| June 2015 | - | $87.25 M(-9.5%) |
| Mar 2015 | - | $96.45 M(-7.3%) |
| Dec 2014 | - | $103.99 M(-21.5%) |
| Sept 2014 | $132.51 M(+593.3%) | $132.51 M(-4.2%) |
| June 2014 | - | $138.35 M(-3.1%) |
| Mar 2014 | - | $142.85 M(+139.2%) |
| Dec 2013 | - | $59.71 M(+212.4%) |
| Sept 2013 | $19.11 M(+466.0%) | $19.11 M(-34.1%) |
| June 2013 | - | $29.03 M(+776.0%) |
| Mar 2013 | - | $3.31 M(+13.1%) |
| Dec 2012 | - | $2.93 M(-13.2%) |
| Sept 2012 | $3.38 M | $3.38 M(+48.0%) |
| June 2012 | - | $2.28 M(-36.5%) |
| Mar 2012 | - | $3.60 M(-46.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | - | $6.77 M(-9.8%) |
| Sept 2011 | $7.51 M(+9.6%) | $7.51 M(+73.9%) |
| June 2011 | - | $4.32 M(-9.9%) |
| Mar 2011 | - | $4.79 M(-12.4%) |
| Dec 2010 | - | $5.47 M(-20.2%) |
| Sept 2010 | $6.85 M(+238.9%) | $6.85 M(-23.8%) |
| June 2010 | - | $8.98 M(+246.4%) |
| Mar 2010 | - | $2.59 M(-31.9%) |
| Dec 2009 | - | $3.81 M(+88.6%) |
| Sept 2009 | $2.02 M(-80.0%) | $2.02 M(+5.8%) |
| June 2009 | - | $1.91 M(-46.3%) |
| Mar 2009 | - | $3.56 M(-53.4%) |
| Dec 2008 | - | $7.64 M(-24.3%) |
| Sept 2008 | $10.09 M(-58.2%) | $10.09 M(-27.0%) |
| June 2008 | - | $13.82 M(-29.2%) |
| Mar 2008 | - | $19.52 M(-23.2%) |
| Dec 2007 | - | $25.42 M(+5.4%) |
| Sept 2007 | $24.12 M(-13.9%) | $24.12 M(+605.0%) |
| June 2007 | - | $3.42 M(-84.2%) |
| Mar 2007 | - | $21.59 M(-23.6%) |
| Dec 2006 | - | $28.27 M(+0.9%) |
| Sept 2006 | $28.02 M(+24.7%) | $28.02 M(+67.9%) |
| June 2006 | - | $16.69 M(+0.6%) |
| Mar 2006 | - | $16.58 M(-13.2%) |
| Dec 2005 | - | $19.11 M(-15.0%) |
| Sept 2005 | $22.47 M(+162.7%) | $22.47 M(-10.6%) |
| June 2005 | - | $25.12 M(+169.8%) |
| Mar 2005 | - | $9.31 M(+37.6%) |
| Dec 2004 | - | $6.77 M(-20.9%) |
| Sept 2004 | $8.55 M(+531.1%) | $8.55 M(-13.1%) |
| June 2004 | - | $9.84 M(-4.8%) |
| Mar 2004 | - | $10.33 M(+623.1%) |
| Dec 2003 | - | $1.43 M(+5.4%) |
| Sept 2003 | $1.36 M(+7225.9%) | $1.36 M(>+9900.0%) |
| June 2003 | - | $5000.00(+1150.0%) |
| Mar 2003 | - | $400.00(-90.0%) |
| Dec 2002 | - | $4000.00(-78.4%) |
| Sept 2002 | $18.50 K(+6066.7%) | $18.50 K(-67.4%) |
| June 2002 | - | $56.80 K(+1858.6%) |
| Mar 2002 | - | $2900.00(+45.0%) |
| Dec 2001 | - | $2000.00(+566.7%) |
| Sept 2001 | $300.00(-85.0%) | $300.00(-70.0%) |
| June 2001 | - | $1000.00(+400.0%) |
| Mar 2001 | - | $200.00(-33.3%) |
| Dec 2000 | - | $300.00(-85.0%) |
| Sept 2000 | $2000.00(+1900.0%) | $2000.00(+300.0%) |
| June 2000 | - | $500.00(-37.5%) |
| Mar 2000 | - | $800.00(+700.0%) |
| Dec 1999 | - | $100.00 |
| Sept 1999 | $100.00(-90.0%) | - |
| Sept 1998 | $1000.00(-16.7%) | - |
| Sept 1997 | $1200.00 | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Arrowhead Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ARWR is $102.69 M
What is the all time high annual cash & cash equivalents for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash & cash equivalents is $221.80 M
What is Arrowhead Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ARWR annual cash & cash equivalents has changed by -$8.21 M (-7.40%)
What is Arrowhead Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ARWR is $102.69 M
What is the all time high quarterly cash and cash equivalents for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash and cash equivalents is $461.03 M
What is Arrowhead Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ARWR quarterly cash and cash equivalents has changed by +$44.47 M (+76.39%)